Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201976 | 0.86 | MAP3K12 (0.34) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL17201973 | 0.86 | PTPN11 (0.47) | GSK3AGSK3BPTPN11PIK3CAMTOR | |
| SCHEMBL17210409 | 0.84 | PIK3CA (0.40) | PTPN11PIK3CAMTORPIK3R1PIK3CD | |
| SCHEMBL23073664 | 0.83 | ROCK1 (0.41) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL22119525 | 0.81 | OGA (0.44) | GSK3AGSK3BPTPN11PIK3CAMTOR | |
| SCHEMBL17202033 | 0.80 | TRPA1 (0.42) | PTPN11PIK3CAMTORPIK3R1FEN1 | |
| SCHEMBL21861322 | 0.76 | MAP3K12 (0.42) | PTPN11PIK3CAMTORMAP3K12 | |
| SCHEMBL18539061 | 0.75 | MTOR (0.38) | PTPN11PIK3CAMTORPIK3R1 | |
| SCHEMBL17202046 | 0.75 | DYRK1A (0.41) | PIK3CAMTORPIK3R1MAP3K12 | |
| SCHEMBL17201970 | 0.75 | PIK3CA (0.35) | PIK3CAMTORPIK3R1MAP3K12FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3134410-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | MERCK & CO., INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015164643-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | GSK3A 2974/4885GSK3B 3474/4885PTPN11 1322/4885 |
| US-20170050966-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPA1, TRPV1, TRPV2 | GSK3A 2974/4885GSK3B 3474/4885PTPN11 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.